※ をクリックすると外部の論文のサイトが開きます。
論文
- タイトル
- タイトル（英）
- An attenuated vaccinia vaccine encoding the SARS-CoV-2 spike protein elicits broad and durable immune responses, and protects cynomolgus macaques and human ACE2 transgenic mice from SARS-CoV-2 and its variants
- 参照URL
- https://researchmap.jp/myportal_saeki-ys/published_papers/39709910
- 著者
- 著者（英）
- Hirohito Ishigaki,Fumihiko Yasui,Misako Nakayama,Akinori Endo,Naoki Yamamoto,Kenzaburo Yamaji,Cong Thanh Nguyen,Yoshinori Kitagawa,Takahiro Sanada,Tomoko Honda,Tsubasa Munakata,Masahiko Higa,Sakiko Toyama,Risa Kono,Asako Takagi,Yusuke Matsumoto,Kaori Hayashi,Masanori Shiohara,Koji Ishii,Yasushi Saeki,Yasushi Itoh,Michinori Kohara
- 担当区分
- 概要
- 概要（英）
- Abstract As long as the coronavirus disease 2019 (COVID-19) pandemic continues, new variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with altered antigenicity will emerge. The development of vaccines that elicit robust, broad, and durable protection against SARS-CoV-2 variants is urgently needed. We have developed a vaccine (rDIs-S) consisting of the attenuated vaccinia virus DIs strain platform carrying the SARS-CoV-2 S gene. rDIs-S induced neutralizing antibody and T-lymphocyte responses in cynomolgus macaques and human angiotensin converting enzyme 2 (hACE2) transgenic mice, and showed broad protection against SARS-CoV-2 isolates ranging from the early-pandemic strain (WK-521) to the recent Omicron BA. 1 variant (TY38-839). Using a tandem mass tag (TMT) -based quantitative proteomic analysis of lung homogenates from hACE2 transgenic mice, we found that, among mice subjected to challenge infection with WK-521, vaccination with rDIs-S prevented protein expression related to the severe pathogenic effects of SARS-CoV-2 infection (tissue destruction, inflammation, coagulation, fibrosis, and angiogenesis) and restored protein expression related to immune responses (antigen presentation and cellular response to stress). Furthermore, long-term studies in mice showed that rDIs-S maintains S protein-specific antibody titers for at least 6 months after a 1st vaccination. Thus, rDIs-S appears to provide broad and durable protective immunity against SARS-CoV-2, including current and possibly future variants.
- 出版者・発行元
- 出版者・発行元（英）
- Cold Spring Harbor Laboratory
- 誌名
- 誌名（英）
- 巻
- 号
- 開始ページ
- 終了ページ
- 出版年月
- 2022年6月13日
- 査読の有無
- 招待の有無
- 掲載種別
- ISSN
- DOI URL
- https://doi.org/10.1101/2022.06.12.495779
- 共同研究・競争的資金等の研究課題